158 related articles for article (PubMed ID: 29588458)
1. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression.
Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
Sci Rep; 2018 Mar; 8(1):5250. PubMed ID: 29588458
[TBL] [Abstract][Full Text] [Related]
2. The impact of estimated tumour purity on gene expression-based drug repositioning of Clear Cell Renal Cell Carcinoma samples.
Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
Sci Rep; 2019 Feb; 9(1):2495. PubMed ID: 30792476
[TBL] [Abstract][Full Text] [Related]
3. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
Li X; Shong K; Kim W; Yuan M; Yang H; Sato Y; Kume H; Ogawa S; Turkez H; Shoaie S; Boren J; Nielsen J; Uhlen M; Zhang C; Mardinoglu A
EBioMedicine; 2022 Apr; 78():103963. PubMed ID: 35339898
[TBL] [Abstract][Full Text] [Related]
4. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
5. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
[TBL] [Abstract][Full Text] [Related]
6. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
7. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
9. Abnormal gene expression profile reveals the common key signatures associated with clear cell renal cell carcinoma: a meta-analysis.
Zhang HJ; Sun ZQ; Qian WQ; Sheng L
Genet Mol Res; 2015 Mar; 14(1):2216-24. PubMed ID: 25867368
[TBL] [Abstract][Full Text] [Related]
10. Screening Novel Drug Candidates for Kidney Renal Clear Cell Carcinoma Treatment: A Study on Differentially Expressed Genes through the Connectivity Map Database.
Gao B; Wang L; Zhang N; Han M; Zhang Y; Liu H; Sun D; Liu Y
Kidney Blood Press Res; 2021; 46(6):702-713. PubMed ID: 34818247
[TBL] [Abstract][Full Text] [Related]
11. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
[TBL] [Abstract][Full Text] [Related]
12. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
13. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.
D'Costa NM; Cina D; Shrestha R; Bell RH; Lin YY; Asghari H; Monjaras-Avila CU; Kollmannsberger C; Hach F; Chavez-Munoz CI; So AI
Sci Rep; 2020 Feb; 10(1):2026. PubMed ID: 32029828
[TBL] [Abstract][Full Text] [Related]
14. Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning.
He J; Yan H; Cai H; Li X; Guan Q; Zheng W; Chen R; Liu H; Song K; Guo Z; Wang X
J Transl Med; 2017 Sep; 15(1):198. PubMed ID: 28962576
[TBL] [Abstract][Full Text] [Related]
15. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
16. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
Wang F; Ding Y; Lei X; Liao B; Wu FX
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
[TBL] [Abstract][Full Text] [Related]
17. Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine.
Wang F; Ding Y; Lei X; Liao B; Wu FX
IEEE J Biomed Health Inform; 2021 Nov; 25(11):4079-4088. PubMed ID: 34665747
[TBL] [Abstract][Full Text] [Related]
18. Efficient generation of patient-matched malignant and normal primary cell cultures from clear cell renal cell carcinoma patients: clinically relevant models for research and personalized medicine.
Lobo NC; Gedye C; Apostoli AJ; Brown KR; Paterson J; Stickle N; Robinette M; Fleshner N; Hamilton RJ; Kulkarni G; Zlotta A; Evans A; Finelli A; Moffat J; Jewett MA; Ailles L
BMC Cancer; 2016 Jul; 16():485. PubMed ID: 27422173
[TBL] [Abstract][Full Text] [Related]
19. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
20. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]